AppTail.

明朝医圣李时珍本草纲目药方大全 - 本草纲目全书

Name: 明朝医圣李时珍本草纲目药方大全 - 本草纲目全书
Author: 小丽 黄

Published by: 小丽黄

View in Store

Downloads

Unlock

last 30 days · worldwide

Revenue

Unlock

last 30 days · worldwide

Description

《本草纲目》，药学著作，五十二卷，明·李时珍撰，刊于1590年。
全书共190多万字，载有药物1892种，收集医方11096个，绘制精美插图1160幅，分为16部、60类。
李时珍在继承和总结以前本草学成就的基础上，结合长期学习、采访所积累的大量药学知识，经过实践和钻研，历时数十年而编成的一部巨著。
《本草纲目》中不仅考正了过去本草学中的若干错误，综合了大量科学资料，提出了较科学的药物分类方法，溶入先进的生物进化思想，并反映了丰富的临床实践。
《本草纲目》不仅仅是我国明代的一部杰出的药物学著作，也是一部集16世纪以前中国本草学之大成的药典，对我国近代药物学的发展有着不可估量的推动作用，在世界范围内也有着极佳的声誉，被誉为“东方药物巨典”。

Hide Show More...

Screenshots

明朝医圣李时珍本草纲目药方大全 FAQ

Is 明朝医圣李时珍本草纲目药方大全 free?

Yes, 明朝医圣李时珍本草纲目药方大全 is completely free and it doesn't have any in-app purchases or subscriptions.
Is 明朝医圣李时珍本草纲目药方大全 legit?

⚠️ The 明朝医圣李时珍本草纲目药方大全 app has poor ratings and negative feedback. Users seem unsatisfied with its performance or features.

Thanks for the vote
How much does 明朝医圣李时珍本草纲目药方大全 cost?

明朝医圣李时珍本草纲目药方大全 is free.
What is 明朝医圣李时珍本草纲目药方大全 revenue?

To get estimated revenue of 明朝医圣李时珍本草纲目药方大全 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating

App is not rated in Israel yet.

View ratings in China

Ratings History

明朝医圣李时珍本草纲目药方大全 Reviews

根本打不开

欺骗下载

软件打开就啥也没有了，刚开始打开说不能联网要连wifi，连上了还是啥也没有，纯纯骗流量骗下载

骗子？

什么都加载不出来，空白的

这个软件根本就打不开，一直停留在加载页面。

不明白为什么打不开的软件要挂在这里给人下载

不知道这是什么APP

我的都打不开

开

打都打不开

空的完全打不开，没有内容

的

啥也出不来

什么也看不到

没有什么

什么都没有

骗子

评你MLGB

Store Rankings

Ranking History

App Ranking History not available yet

Category Rankings

App is not ranked yet

明朝医圣李时珍本草纲目药方大全 Installs

Last 30 days

-1

View Installs Data

明朝医圣李时珍本草纲目药方大全 Revenue

Last 30 days

$-1

View Revenue Data

明朝医圣李时珍本草纲目药方大全 Revenue and Downloads

Gain valuable insights into 明朝医圣李时珍本草纲目药方大全 performance with our analytics.
Sign up now to access downloads, revenue, and more.

App Info

Category: Medical
Publisher: 小丽黄
Languages: English
Recent release: 1.0 (9 years ago )
Released on: Dec 1, 2015 (9 years ago )
Also available in: China, United States, Malaysia, Taiwan, Canada, Thailand, Australia, Japan, Poland, Saudi Arabia, United Kingdom, Tunisia, Sweden, Belgium, Nigeria, Netherlands, Austria, Mexico, Israel, Pakistan, Norway, Vietnam, Brazil, Greece, Portugal, Ukraine, New Zealand, Indonesia, Türkiye, Switzerland, Colombia, Peru, Ireland, Azerbaijan, Egypt, Belarus, Argentina, Ecuador, United Arab Emirates, South Korea, Lebanon, Dominican Republic, Philippines, Russia, Romania, Kazakhstan, Czechia, Spain, Bulgaria, Italy, South Africa, Denmark, Finland, Germany, Malta, Kuwait

Last Updated: 2 weeks ago

This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.